CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Burzynski Research Institute Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Burzynski Research Institute Inc
12000 Richmond Ave
Phone: (713) 335-5697p:713 335-5697 HOUSTON, TX  77082  United States Ticker: BZYRBZYR
Business Summary
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and are reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
8/31/20242/29/2024YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President Stanislaw R.Burzynski 80 2/29/2012 1/1/1984
Vice President - Clinical Trials TomaszJanicki 57 3/1/2012 3/1/2012
Treasurer, Secretary Patryk P.Goscianski 45 3/1/2012 3/1/2012
Director Gregory S.Burzynski 43 9/8/2011 9/8/2011
Director MonikaSzopa - Paszkowiak 59 10/6/2021 10/6/2021

Business Names
Business Name
Burzynski Research Institute
Burzynski Research Institute
BURZYNSKI RESEARCH INSTITUTE INC
Burzynski Research Institute, Inc.
BZYR

General Information
Number of Employees: 2 (As of 2/28/2014)
Outstanding Shares: 131,448,444 (As of 8/31/2024)
Shareholders: 2,000
Stock Exchange: OTC
Federal Tax Id: 760136810
Fax Number: (713) 935-0649


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024